<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411656</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0533</org_study_id>
    <secondary_id>NCI-2015-00671</secondary_id>
    <nct_id>NCT02411656</nct_id>
  </id_info>
  <brief_title>MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)</brief_title>
  <official_title>A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      You are being asked to take part in this study because you have inflammatory breast cancer
      (IBC) or triple negative breast cancer (TNBC) that is metastatic (has spread to other parts
      of the body).

      The goal of this clinical research study is to learn if pembrolizumab (also called MK-3475
      and Keytruda) can help to control metastatic IBC and TNBC. The safety of this drug will also
      be studied.

      This is an investigational study. Pembrolizumab is FDA approved and commercially available
      for the treatment of metastatic melanoma. Its use in patients with metastatic IBC and TNBC is
      investigational. The study doctor can describe how the study drug is designed to work.

      Up to 35 participants will be enrolled in this study. All will take part in at MD Anderson.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration:

      If you are found to be eligible to take part in this study, you will receive pembrolizumab by
      vein over about 30 minutes on Day 1 (+/- 3 days) of each 21-day cycle.

      Study Visits:

      On Day 1 of each cycle:

        -  You will have a physical exam.

        -  Blood (about 2-3 tablespoons) will be drawn for routine tests.

      At Cycles 3, every 3rd cycle after that (Cycles 6, 9, 12, and so on), and if the disease gets
      worse, blood (about 10 tablespoons) will be drawn for biomarker and immune system testing.

      About every 2 Cycles, you will have imaging scans to check the status of the disease as part
      of standard of care. .

      Length of Study:

      You may continue taking the study drug for up to 24 months, as long as the doctor thinks it
      is in your best interest. You will no longer be able to take the study drug if the disease
      gets worse, if intolerable side effects occur, or if you are unable to follow study
      directions.

      Your participation on the study will be over after the follow-up visits.

      End-of-Treatment Visit:

      After you stop receiving the study drug:

        -  You will have a physical exam.

        -  Blood (about 10 tablespoons) will be drawn for routine tests.

        -  You will have the same imaging scans you had at screening to check the status of the
           disease.

      Follow-Up:

      About 1 and 3 months after the last dose of study drug, you will be asked about your health
      and any side effects you may have had. You may be asked during a routine clinic visit or you
      may be called. If you are called, each call should last about 2 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>4 months</time_frame>
    <description>Disease control rate defined as the percentage of patients either 1) with measurable disease that maintain complete response (CR) or partial response (PR), or upgrade from PR to CR, or 2) with non-measurable disease that remain CR or stable disease (SD), or upgrade from SD to CR, by 4 months or more in all evaluable patients.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>MK-3475</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-3475 200 mg administered on Day 1 of each 21 day cycle as a 30 minute infusion by vein for up up to 24 months.
Follow up or phone call about 1-3 months after last dose of study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3475</intervention_name>
    <description>200 mg administered on Day 1 of each 21 day cycle as a 30 minute infusion by vein.</description>
    <arm_group_label>MK-3475</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Pembrolizumab</other_name>
    <other_name>SCH-900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Follow Up/Phone Call</intervention_name>
    <description>About 1 and 3 months after last dose of study drug, participant to have follow up or phone call. If participant is called, each call should last about 2 minutes.</description>
    <arm_group_label>MK-3475</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is willing and able to provide written informed consent for the trial.

          2. Is a female or male and &gt;/= 18 years of age

          3. A).Has histological confirmation of HER2 normal breast carcinoma with a clinical
             diagnosis of IBC based on presence of inflammatory changes in the involved breast,
             including diffuse erythema and edema (peau d'orange), with or without an underlying
             palpable mass involving the majority of the skin of the breast. Pathological evidence
             of dermal lymphatic invasion should be noted but is not required for diagnosis of
             inflammatory breast cancer regardless ER/PR status; OR B).Has histological
             confirmation of triple negative breast carcinoma (HER2 normal, ER/PR &lt; 10%) without
             clinical diagnosis of IBC

          4. Has stage IV or recurrent disease that has been treated

          5. Has clinical response or stable disease for minimum of two months (three cycle of
             every three week chemotherapy or 8 weeks of weekly regimen, etc.) after receiving any
             prior chemotherapy for metastatic/recurrent disease. A minimum of two cycles (6-8
             weeks) of chemotherapy is required to determine clinical response. Per RECIST criteria
             1.1, Clinical response for measurable disease is defined as complete response (CR) or
             partial response (PR); for non-measurable disease only (i.e. bone metastasis, ascites,
             pleural effusion, and pathological lymph nodes &gt;/= 10 to &lt;15 mm short axis) is defined
             as persistence of one or more non-target lesion(s) and no increase in overall tumor
             burden.

          6. Is HER2 normal, defined as HER2 0 or 1+ by IHC and negative by FISH if performed; or
             HER2 is 2+ by IHC and negative by FISH; or HER2 negative by FISH if IHC is not
             performed.

          7. Has a performance status of 0-1 on the ECOG Performance Scale.

          8. Has adequate organ function as determined by the following laboratory values: ANC &gt;/=
             1,500 /mcL, Platelets &gt;/=100,000 /mcL, Hgb &gt;/= 9 g/dL, creatinine levels &lt; 1.5 x ULN,
             Total bilirubin &lt;/= 1.5 x ULN, ALT and AST &lt;/= 2.5 x ULN or &lt;/=5 x ULN for subjects
             with liver metastases.

          9. Subjects of childbearing potential should be willing to use effective methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study through at least 4 months after the last dose of study drug.Subjects of
             childbearing potential are those who have not been surgically sterilized or have not
             been free from menses for &gt; 1 year. Effective methods of birth control include 1). Use
             of hormonal birth control methods: pills, shots/injections, implants (placed under the
             skin by a health care provider), or patches (placed on the skin); 2).Intrauterine
             devices (IUDs); 3).Using 2 barrier methods (each partner must use 1 barrier method)
             with a spermicide. Males must use the male condom (latex or other synthetic material)
             with spermicide. Females must choose either a Diaphragm with spermicide, or Cervical
             cap with spermicide, or a sponge (spermicide is already in the contraceptive sponge).

         10. Has negative serum or urine pregnancy test for subjects of childbearing potential.

        Exclusion Criteria:

          1. Is currently participating in a study of an investigational anti-cancer agent.

          2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy.

          3. Has not recovered from adverse events due to prior therapies, i.e. monoclonal
             antibody, chemotherapy, targeted small molecule therapy, radiation therapy, or
             surgery.( Note: Subjects with â‰¤ Grade 2 neuropathy, alopecia and general disorders and
             administration site conditions (per CTCAE version 4.0) are an exception to this
             criterion and may qualify for the study.)

          4. Has a known malignancy (other than breast cancer) except basal cell carcinoma or
             squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone
             potentially curative therapy.

          5. Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate if they
             are stable, and have no evidence of new or enlarging brain metastases, and are not
             using steroids for at least 7 days prior to trial treatment.

          6. Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or
             resolved childhood asthma/atopy would be an exception to this rule. Subjects that
             require intermittent use of bronchodilators or local steroid injections would not be
             excluded from the study. Subjects with hypothyroidism stable on hormone replacement or
             Sjorgen's syndrome will not be excluded from the study.

          7. Has a history of (non-infectious) pneumonitis that required steroids or current
             pneumonitis.

          8. Has an active infection requiring systemic therapy.

          9. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         10. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways) within 3 months.

         11. Has a known history of Human Immunodeficiency Virus (HIV).

         12. Has a known active Hepatitis B or Hepatitis C

         13. Have received a live vaccine within 30 days prior to the first dose of trial
             treatment.

         14. Is receiving concurrent anti-cancer therapy for metastatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto Ueno, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naoto Ueno, MD, PHD</last_name>
    <phone>713-792-2817</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Metastatic inflammatory breast cancer</keyword>
  <keyword>MIBC</keyword>
  <keyword>IBC</keyword>
  <keyword>Breast carcinoma</keyword>
  <keyword>Metastatic</keyword>
  <keyword>MK-3475</keyword>
  <keyword>Keytruda</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>SCH-900475</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

